Evariste
Evariste is a London-based TechBio company that uses its proprietary AI platform Frobenius to discover synthetic lethal oncology targets and design small molecule therapeutics, partnering with pharmaceutical companies and academic institutions on platform licensing and pipeline asset deals.
- Company typePrivate
- Founded2017
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Evariste does
Evariste is a London-based TechBio company that applies its AI-enabled drug discovery platform, Frobenius, to identify novel synthetic lethal targets in oncology and design small molecule therapeutics against them. The Frobenius platform combines machine learning, probabilistic modeling, and physics-based simulations, organized into two integrated modules: Frobenius Target, which analyzes multi-omic datasets to uncover synthetic lethal relationships and biomarkers, and Frobenius Discovery, which performs virtual screening, multi-parameter optimization, and free energy calculations to produce differentiated drug candidates. Distinctive technical components include Non-Equilibrium Switching (NES) free energy calculations, the Dynamic Pose Database (PoseDB), Bayesian uncertainty modeling that separates aleatoric and epistemic noise, and proprietary automated compound design algorithms producing on the order of 10^6 molecules per design cycle. Evariste's preclinical pipeline centers on a nominated PKMYT1 development candidate (EVT-3023), a VRK1 program for glioblastoma, and 10+ additional synthetic lethal programs across AML, DLBCL, NSCLC, CRC, ovarian, and other cancers.
Evariste operates a B2B partnership and licensing model rather than selling discrete products. Revenue streams take three forms: platform licensing and preclinical research agreements with pharmaceutical companies (exemplified by a December 2024 preclinical collaboration with Finland's Orion Corporation); licensing of pipeline assets such as EVT-3023; and collaborative research arrangements with academic institutions including the University of Southampton (for proprietary oesophageal adenocarcinoma datasets) and the Institute of Cancer Research. The company also leverages incubator and ecosystem programs such as the Servier Golden Ticket and NVIDIA Inception. Distribution is entirely through direct enterprise engagement; no standard pricing tiers are published. Customers are concentrated among large pharmaceutical companies seeking differentiated oncology targets and academic centers providing translational datasets and validation.
The company is privately held, was founded around 2017, and operates with a small team of 1-10 employees that is multidisciplinary across drug discovery, mathematics, and AI. Leadership includes CEO Anna Hercot, CSO Alfie Brennan (ex-Institute of Cancer Research), Head Quant Oliver Vipond (Oxford math PhD), and a scientific board that includes former AstraZeneca Tagrisso chemistry lead Mike Waring and ICR's Olivia Rossanese. Evariste is in the process of launching a second product line, Blaise AI, positioned as a next-generation AI tool for small molecule analysis.
Evariste firmographics
Firmographics- Name
- Evariste
- Legal name
- Evariste Ltd
- Website
- https://evariste.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Evariste is a London-based TechBio company that uses its proprietary AI platform Frobenius to discover synthetic lethal oncology targets and design small molecule therapeutics, partnering with pharmaceutical companies and academic institutions on platform licensing and pipeline asset deals.
- Ownership category
- akta.pro rank
Evariste industry classification
Industry- Product category
- AI-Enabled Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)
Keywords
Where Evariste is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Evariste business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Licensing and Collaboration Agreements: Evariste licenses its Frobenius platform to pharmaceutical partners for drug discovery programs. Collaborations include preclinical research agreements where Evariste designs inhibitors for partner-selected targets using its full suite of ML algorithms and compound designers.
- Pipeline Asset Licensing: The company seeks licensing deals for innovative pipeline assets, including development candidates like EVT-3023 PKMYT1 inhibitor and other preclinical programs targeting novel synthetic lethal targets.
- Collaborative Research and Development: Strategic partnerships with pharmaceutical companies and academic institutions for joint discovery programs, combining Evariste's AI platform capabilities with partner resources and expertise.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Evariste product offering
Product offeringCore offering
Evariste discovers novel synthetic lethal oncology targets and designs small molecule therapeutics using its AI-enabled Frobenius platform. The company operates two integrated platform modules — Frobenius Target for novel target and biomarker identification through multi-omic data analysis, and Frobenius Discovery for automated small molecule design and multi-parameter optimization. Evariste also develops an internal pipeline of precision oncology assets (including the EVT-3023 PKMYT1 inhibitor and a VRK1 inhibitor) that it licenses to pharmaceutical partners through preclinical research agreements and pipeline asset licensing deals.
Product overview
Evariste is an AI-enabled drug discovery company offering a platform-based approach centered on the Frobenius AI drug discovery platform. The platform consists of two main integrated modules: Frobenius Target for identification of novel synthetic lethal targets and biomarkers through multi-omic data analysis, and Frobenius Discovery for small molecule drug design using virtual screening, machine learning-driven optimization, and physics-based simulations. The company also announced the launch of Blaise AI as the next generation of AI for small molecule analysis. ESA Scoring is an additional feature within Frobenius Discovery that automates synthetic accessibility assessment for compound prioritization.
Differentiator
Problem solved
Functional benefit
Brands
- Blaise AI: Next generation AI for small molecule analysis - launching product
- Frobenius
- Frobenius Target
- Frobenius Discovery
Products and services
- Frobenius Evariste's AI-enabled drug discovery platform that integrates target identification, small molecule design, and optimization capabilities. Frobenius uses machine learning, probabilistic modeling, and physics-based simulations to discover and develop novel small molecule therapeutics targeting synthetic lethal pathways in oncology. The platform is licensed to pharmaceutical partners through preclinical research agreements.
- Blaise AI Next-generation AI system for small molecule analysis, described as 'the next generation of AI for small molecule analysis'. It represents a new product launch extending Evariste's AI capabilities beyond the Frobenius platform.
- EVT-3023 (PKMYT1 inhibitor) Pipeline development candidate targeting PKMYT1, which drives synthetic lethality in cancer cells with high replication stress. EVT-3023 is well-tolerated and efficacious in multiple tumor models and shows best-in-class potency and selectivity over key off targets including WEE1 and the Raf family. Available for licensing to pharmaceutical partners.
- VRK1 inhibitor program Pipeline program targeting VRK1 inhibition, which is synthetic lethal with VRK2 under-expression. VRK1 is highly ranked as a target in glioblastoma and neuroblastoma. There are no clinical competitors for this target and Evariste has designed potent inhibitors optimized for CNS permeability. Available for licensing to pharmaceutical partners.
- Novel synthetic lethal target program (undisclosed) Pipeline program targeting an undisclosed metabolic enzyme for heavily pretreated hematological malignancies. The synthetic lethal target is present in a subset of acute myeloid leukemia and diffuse large B-cell lymphoma patients, as well as in HR-deficient solid tumors. Evariste has designed the first ever inhibitors for this target. Available for licensing to pharmaceutical partners.
Quantifiable outcome
- Achieved best-in-class potency and selectivity in fewer than 50 compounds, with roughly 10-fold potency increase for every 30 compounds tested
- +4 more outcomes
Companies that use Evariste
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Evariste technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability10 records
Feature8 records
Evariste partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Institute of Cancer Research (ICR)coreDirector of Drug Discovery and Head of Division for Cancer Therapeutics at ICR (Olivia Rossanese) serves on Evariste's Board of Directors. Formerly a member of GSK's Tafinlar discovery team with extensive experience in discovery and target validation programs.
- Servier (Spartners by Servier & BioLabs)coreEvariste won the Servier Golden Ticket award, receiving a year's residence at Spartners by Servier & BioLabs incubator at Servier's R&D Institute in Paris-Saclay. Provides access to shared fully-equipped laboratories, BioLabs network, Servier's state-of-the-art laboratories, mentorship from industry experts, and operational resources for therapeutic innovation development.
- University of SouthamptoncoreEvariste partnered with the University of Southampton's School of Cancer Sciences to generate one of the largest clinically annotated transcriptomic datasets in oesophageal adenocarcinoma (OAC). Evariste applies its AI-driven discovery engine to identify novel therapeutic targets for OAC patients who currently have very few targeted treatment options.
- Orion CorporationcoreEvariste entered into a preclinical research agreement with Orion Corporation, a leading Finnish pharmaceutical company. Under the agreement, Evariste uses its Frobenius Discovery platform to design small molecule inhibitors for a target selected by Orion. The collaboration deploys the full suite of proprietary ML algorithms, automated compound designers, and accelerated free energy calculations to deliver potential candidate molecules.
- OpenSource Malaria Project (Professor Mat Todd, UCL)minorEvariste contributed to the OpenSource Malaria project coordinated by Professor Mat Todd at UCL. Used Frobenius platform to design and synthesize novel anti-malarial compounds. Project included automated library construction, ML-based scoring, and compound selection using pessimistic design algorithm.
- PostEra (Covid Moonshot)minorEvariste contributed to the Covid Moonshot project coordinated by PostEra, focused on identifying drugs targeting the SARS-CoV-2 main protease. Used Frobenius platform to generate novel compound designs and contribute to the open science drug discovery effort.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Evariste competitors and assessment
Company assessmentDirect peers
- Exscientia: AI-driven precision medicine company focused on small molecule drug discovery using its proprietary Centaur AI platform. Comparable to Evariste in platform-based small molecule design with active pharma partnerships and pipeline assets, though more clinically advanced.
- Tango Therapeutics: Synthetic lethality-focused oncology company with multiple clinical-stage programs and a platform approach to identifying novel SL targets. Direct peer to Evariste in the synthetic lethality space, especially around discovery of novel targets and biomarker-driven patient selection.
- Artios Pharma: DNA damage response and synthetic lethality company developing small molecule therapeutics in oncology. Comparable to Evariste on the synthetic lethal mechanism of action and on being a UK/European oncology platform with multiple programs.
- Insilico Medicine: AI-driven drug discovery company using deep learning, generative chemistry, and biology to identify targets and design molecules. Comparable platform-plus-pipeline model to Evariste with both internal pipeline and pharma collaborations; competes directly in the AI-enabled small molecule space.
- XtalPi: AI-driven pharmaceutical technology company combining physics-based modeling, quantum chemistry, and ML for small molecule discovery. Comparable to Evariste in computational chemistry capabilities and in offering both platform services and internal pipeline assets.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel targets and small molecule candidates. Directly comparable to Evariste in using AI/ML to power target identification and chemistry, with a similar platform-plus-pipeline model in oncology and other therapeutic areas.
- Repare Therapeutics: Precision oncology company developing synthetic lethal and DNA damage response (DDR) therapies, including a clinical-stage PKMYT1 inhibitor (RP-3467). Most directly comparable to Evariste on the synthetic lethality/PKMYT1 axis, and a benchmark for the value-creation potential of Evariste's lead asset.
Emerging players
- Iambic Therapeutics: AI-driven drug discovery company combining physics-based simulation with machine learning for clinical-stage small molecule design. Comparable to Evariste in technical approach (physics + ML for chemistry) and small molecule focus, but more clinically advanced.
- Cradle Bio: AI platform for protein and small molecule design serving biotech and pharma partners. Comparable emerging player to Evariste in platform-based AI for early-stage drug discovery, though focused on protein engineering rather than synthetic lethal target identification.
Broad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery company building on DeepMind's AlphaFold to discover and design new drugs. Comparable in using AI/ML and physics-based modeling for drug discovery, but with substantially greater resources and a broader therapeutic scope than Evariste.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Evariste social profiles
Digital presenceEvariste financial estimates
Financial estimateRevenue estimate
Valuation estimate
Evariste leadership team
Management profileNumber of profiles
Profiles17 records
Evariste funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Evariste M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Evariste
What does Evariste do?
Evariste discovers novel synthetic lethal oncology targets and designs small molecule therapeutics using its AI-enabled Frobenius platform. The company operates two integrated platform modules — Frobenius Target for novel target and biomarker identification through multi-omic data analysis, and Frobenius Discovery for automated small molecule design and multi-parameter optimization. Evariste also develops an internal pipeline of precision oncology assets (including the EVT-3023 PKMYT1 inhibitor and a VRK1 inhibitor) that it licenses to pharmaceutical partners through preclinical research agreements and pipeline asset licensing deals.
Is Evariste a public or private company?
Evariste is a private company. It is classified as venture growth investor backed and is currently operating.
When was Evariste founded?
Evariste was founded in 2017. It employs 1 to 10 people.
Where is Evariste based?
Evariste is headquartered in London, United Kingdom, in the Europe region.
How does Evariste make money?
Three revenue lines are on record. Platform Licensing and Collaboration Agreements are the primary driver. The others are pipeline Asset Licensing and collaborative Research and Development.
Who are Evariste's main competitors?
Direct peers on record are Exscientia, Tango Therapeutics, Artios Pharma, Insilico Medicine, XtalPi, Recursion Pharmaceuticals and Repare Therapeutics. Emerging players are Iambic Therapeutics and Cradle Bio. Isomorphic Labs is listed as a broad incumbent.
Does Evariste have an API?
No public API is recorded for Evariste.
What industry is Evariste in?
Evariste's product category is AI-Enabled Drug Discovery Platform. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.